- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03933800
High Flow Nasal Cannula Therapy for Childhood OSA
High-flow Nasal Cannula as an Alternative Intervention for Children and Adolescents With Obstructive Sleep Apnoea
The main objective of this study is to evaluate the efficacy of high-flow nasal cannula (HFNC) therapy in children with OSA.
Children and adolescents aged 6 to 18 years old with a diagnosis of moderate-to-severe OSA requiring CPAP therapy will be recruited.
In phase 1 study, eligible subject will be recruited for HFNC therapy titration with PSG to assess treatment efficacy. After titration, if HFNC therapy is shown to be effective, the participants will be recruited into the phase 2 intervention period to evaluate the compliance and quality of life with HFNC therapy. At baseline and follow-up visits, neurobehavioural and quality of life surveys will be completed, compliance data will be obtained.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background: Obstructive sleep apnoea (OSA) is prevalent in school-aged children and is associated with significant morbidities. Poor compliance with positive airway pressure therapy remains an issue and leads to suboptimal treatment in children with OSA. Alternative therapeutic strategy is needed to manage this group of patients more effectively.
Objective: To evaluate the efficacy of high-flow nasal cannula (HFNC) therapy in children with OSA.
Hypothesis: The investigators hypothesize that HFNC therapy is effective in reducing the severity of OSA in children.
Design: A 2-phase study - phase 1 is a single arm study to evaluate the efficacy of HFNC therapy in children with OSA, phase 2 is an intervention period to evaluate the compliance and quality of life with HFNC therapy.
Subjects: 46 children and adolescents aged 6 to 18 years old with a diagnosis of moderate-to-severe OSA requiring CPAP therapy.
Methods: In phase 1 study, eligible subject will be recruited for HFNC therapy titration with PSG to assess treatment efficacy. After titration, if HFNC therapy is shown to be effective, the participants will be recruited into the phase 2 intervention period to evaluate the compliance and quality of life with HFNC therapy. At baseline and follow-up visits, neurobehavioural and quality of life surveys will be completed, compliance data will be obtained.
Primary outcome measure: Efficacy of the HFNC therapy, as defined by the change in OAHI from baseline to that with HFNC therapy.
Expected results: Efficacy data to determine whether HFNC therapy can be an alternative therapy for children with OSA.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Hong Kong, Hong Kong
- Prince of Wales Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of moderate-to-severe OSA requiring CPAP therapy (Moderate-to-severe OSA is defined as an OAHI ≥ 5 events per hour and reported history of habitual snoring of 3 nights or more per week)
Exclusion Criteria:
- Syndromal diseases;
- Cranio-facial anomalies;
- Pathological central apnoea, chronic respiratory failure or neuromuscular disease as they would require bilevel PAP;
- Secondary obesity e.g. Prader-Willi syndrome, Cushing's syndrome;
- History of pneumothorax or pneumomediastinum;
- Prior use of PAP or HFNC therapy;
- Refusal to use non-invasive ventilation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: High flow nasal cannula (HFNC)
High flow nasal cannula therapy
|
High flow nasal cannula therapy
|
Active Comparator: Continuous positive airway pressure (CPAP)
Continuous positive airway pressure therapy
|
Continuous positive airway pressure therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of the high flow nasal cannula (HFNC) therapy: the absolute change in obstructive apnea hypopnea index (OAHI) from baseline with the use of HFNC therapy
Time Frame: One night - titration study will be done overnight for one night to look at the improvement of OAHI from baseline to that with HFNC therapy
|
The change in obstructive apnea hypopnea index (OAHI) from baseline to that on HFNC therapy: obstructive apnoea hypopnoea index is the number of obstructive apnoea or hypopnoea events per hour of total sleep time (It is not a scale, minimum is 0 events/hour, there is no maximum score)
|
One night - titration study will be done overnight for one night to look at the improvement of OAHI from baseline to that with HFNC therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compliance to the therapy: percentage of subjects who are adherent to the therapy
Time Frame: 3 months
|
Percentage of subjects who are adherent to the therapy, which is defined as >70% nightly use and average usage ≥ 4 hours per night
|
3 months
|
Quality of life measures - Modified Epworth Sleepiness Scale
Time Frame: 3 months
|
Modified Epworth Sleepiness Scale (ESS) to assess the daytime sleepiness - ESS score is the sum of the eight item scores ranging from 0 to 24, where a higher score represents greater sleepiness.
|
3 months
|
Quality of life measures - Pediatric Quality of Life Inventory
Time Frame: 3 months
|
Pediatric Quality of Life Inventory (PedsQL) - 23-item PedsQL Generic Core Scales will measure the core dimensions of health as delineated by the World Health Organisation, as well as role functioning.
Four dimensions, physical, emotional, social and school functioning, will be measured.
For physical functioning, score ranges from 1 to 8.
For emotional, social and school functioning, scores range from 1 to 5. Higher scores indicate better quality of life.
|
3 months
|
Quality of life measures - OSAS-18
Time Frame: 3 months
|
OSAS-18 is a questionnaire with composite of OSAS-related symptoms and disease-specific quality of life.
Score ranges from 18 to 126; 18 - 60 indicates small impact on health-related quality of life; 60 to 80 indicates moderate impact; >80 indicates severe impact.
|
3 months
|
Neurobehavioural surveys - Child Behaviour Checklist
Time Frame: 3 months
|
Child Behaviour Checklist is a survey of behaviour competencies that yields standardised, age-adjusted scores on internalizing, externalizing and total behaviour difficulties
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kate C Chan, MBChB, Chinese University of Hong Kong
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HFOSA1.0
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obstructive Sleep Apnea
-
LivaNovaActive, not recruitingApnea | Obstructive Sleep Apnea | OSA | Apnea, Obstructive | Apnea+Hypopnea | Apnea, Obstructive Sleep | Hypopnea, SleepUnited States
-
Mauro ManconiCompletedObstructive Sleep Apnea Syndrome | Sleep Apnea, Obstructive | Obstructive Sleep Apnea | OSA | Apnea, Obstructive | OSAHSwitzerland
-
University of California, Los AngelesRecruiting
-
Brigham and Women's HospitalCompletedObstructive Sleep Apnea (OSA)United States
-
ApnimedCompletedOSA - Obstructive Sleep ApneaUnited States
-
State Budgetary Healthcare Institution, National...RecruitingObstructive Sleep Apnea | Obstructive Sleep Apnea-hypopnea | Obstructive Sleep Apnea-hypopnea SyndromeRussian Federation
-
The Hospital for Sick ChildrenCompleted
-
Cryosa, Inc.Active, not recruitingObstructive Sleep Apnea of AdultPanama, Paraguay
-
State Key Laboratory of Respiratory DiseaseCompletedObstructive Sleep Apnea of AdultChina
-
Somnics, Inc.UnknownObstructive Sleep Apnea of AdultTaiwan
Clinical Trials on High flow nasal cannula
-
Aga Khan University Hospital, PakistanUnknownApneic Oxygenation
-
Hospital Clinic of BarcelonaUnknownPatient Population Submitted to ERCPSpain
-
Kuopio University HospitalCentral Finland Hospital District; Mikkeli Central Hospital; Siun soteRecruiting
-
Montefiore Medical CenterCompletedMorbid Obesity | Noninvasive Ventilation | Deep SedationUnited States
-
Samsung Medical CenterFisher and Paykel HealthcareRecruitingAcute Respiratory FailureKorea, Republic of
-
Children's Hospital Los AngelesCompletedHigh Flow Nasal CannulaUnited States
-
Mount Sinai Hospital, CanadaPrincess Margaret Hospital, CanadaActive, not recruitingHypoxia | Hematologic Malignancy | Immunocompromised | Post Hematopoietic Stem Cell Transplant | Pulmonary InfiltratesCanada
-
Rush University Medical CenterMedical College of Wisconsin; Hospital Civil de GuadalajaraRecruitingObesity, Morbid | Extubation FailureUnited States, Mexico
-
Assistance Publique - Hôpitaux de ParisCompleted